Addictions Therapeutics Market 2023-2027 Along with 5-Year Historic (2017-2021) Industry Size & Comparison of 20 Vendors and 11 Countries

NEW YORK, Oct. 20, 2022 /PRNewswire/ -- The Addictions Therapeutics Market share is expected to increase by USD 9.86 billion from 2022 to 2027, with an accelerated CAGR of 7.65% - according to the recent market study by Technavio. This report also offers a 5-year historic (2017-2021) data projection of market size, segment, and region. The Y-O-Y growth rate of the Addictions Therapeutics Market is estimated at 6.56% as of 2023. Moreover, the market is fragmented. Our analysts have conducted an internal and external analysis of vendors to help companies understand the wider business environment as well as the strength and weaknesses of key market players. Our report also forecasts the Bargaining Power of Buyers & Suppliers and the Threat of New Entrants & Rivalry ranging between LOW-HIGH during the forecast period.

• One of the core component of customer landscape is Price Sensitivity – an analysis of which will help companies refine marketing strategies to gain a competitive advantage.   
• Moreover, this report also provides impact of price sensitivity drivers (purchases are undifferentiated, purchase is a key cost to the buyer, and quality is not important) which are expected to range between LOW-HIGH from 2023-2027.
• Our report provides extensive information on the customer landscape of the Addictions Therapeutics market, involving qualitative and quantitative intelligence. 

FOR DETAILED OVERVIEW ON CUSTOMER LANDSCAPE REQUEST SAMPLE PAGES

• Amneal Pharmaceuticals Inc.
• Aphios Corp.
• Braeburn Inc.
• Emergent BioSolutions Inc.
• GlaxoSmithKline Plc
• Glenmark Pharmaceuticals Ltd.
• Hikma Pharmaceuticals Plc
• Indivior Plc
• Johnson and Johnson
• Kaleo Inc.
• Mallinckrodt Plc
• Orexo AB
• Otsuka Holdings Co. Ltd.
• Pfizer Inc.
• Purdue Pharma LP
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd.
• Titan Pharmaceuticals Inc.
• Viatris Inc.

DOWNLOAD SAMPLE REPORT FOR MORE ACCESS

• The market is segmented by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Others) and Type (Alcohol Addiction Therapeutics, Tobacco Addiction Therapeutics, and Drug Addiction Therapeutics).
• By Distribution Channel - The hospital pharmacy segment shows a gradual increase in the demands for construction and other factors during 2023-2027.
• Owing to the good discounts, improving reimbursement, and the growing number of drug addicts, hospital pharmacies experience increasing demand for addiction therapeutics. These factors will positively impact the growth of the hospital pharmacy segment of the global addiction therapeutics market during the forecast period.
• The growth of this segment is primarily attributed to the increasing adoption of the Addictions Therapeutics Market by residential consumers, which is driven by changing lifestyles and a growing preference for comfort.

INTERESTED TO PROCURE THE DATA?
DOWNLOAD SAMPLE REPORT

Despite increasing awareness about and stringent regulations on the consumption of these products, the market has witnessed an increase in the consumption of alcohol, opioids, and tobacco products. Opioids are a type of narcotic pain medication that is available as a therapy for the treatment of moderate-to-severe pain in many developed countries. However, the misuse and abuse of opioids lead to opioid tolerance and addiction. The high consumption of alcohol, tobacco, and opioid products on a daily basis can lead to a strong desire or sense of compulsion to consume the substance. This results in complications in controlling substance use behavior in terms of its onset, termination, and levels of use, which leads to substance use disorder, also known as substance dependency. Owing to the high consumption of these substances, the prevalence of substance use disorders has increased globally. Hence, the high consumption of these substances increases the prevalence of addiction globally, thereby driving the market growth.

TO ACCESS WHAT ARE THE LATEST DRIVERS, TRENDS, AND CHALLENGES INFLUENCING THE GROWTH OF THIS MARKET? REQUEST SAMPLE REPORT

• The market is segmented by Geography North America (The U.S. and Canada), Europe (U.K., Germany, France, and Rest of Europe), Asia (China, India, Japan, and South Korea), and Rest of World (ROW).
• North America is projected to grow at a percentage of 45% by 2022. North America was the most significant contributing region in the global addictions therapeutics market, primarily owing to the increasing consumption of alcohol, tobacco, and opioids in the US and Canada. The consumption of alcohol, tobacco, and opioids is the leading cause of addiction in the US. The prevalence remains high among adults with mental health, disability, and substance use disorders. 
• In 2020, the COVID-19 pandemic negatively impacted most North American countries, which resulted in the temporary closure of various industries, including those manufacturing addiction therapeutics. The shutdowns adversely impacted their production and distribution activities. Also, as online channels were active even during the pandemic, there was an increased demand for addiction therapeutics. However, in 2021, the demand for addiction therapeutics rebounded from offline retail stores as regional activities resumed due to the COVID-19 vaccination drives and the subsequent lifting of lockdown restrictions. 

FOR MORE INSIGHTS ON THE MARKET SHARE OF VARIOUS REGIONS VIEW PDF SAMPLE NOW!

Alzheimers Disease Therapeutics Market by Drug Class and Geography - Forecast and Analysis 2022-2026 – The market share is expected to increase by USD 3.99 billion from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 8.76%. Furthermore, this report extensively covers market segmentations by drug class (cholinesterase inhibitors, N-methyl-D-aspartate receptor antagonists, and other drug class) and geography (North America, Europe, Asia, and Rest of World (ROW)).  To get more exclusive research insights: VIEW SUMMARY OF THE REPORT FOR MORE 

Gastrointestinal Stromal Tumors Therapeutics Market by Route of Administration and Geography - Forecast and Analysis 2022-2026 – The market share is expected to increase by USD 1.08 billion from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 5.97%. The growing geriatric population is one of the key factors driving the market growth. To get more exclusive research insights: VIEW SUMMARY OF THE REPOR FOR MORE

1 Executive Summary

• 1.1 Market overview
• Exhibit 01: Executive Summary – Chart on Market Overview
• Exhibit 02: Executive Summary – Data Table on Market Overview
• Exhibit 03: Executive Summary – Chart on Global Market Characteristics
• Exhibit 04: Executive Summary – Chart on Market by Geography
• Exhibit 05: Executive Summary – Chart on Market Segmentation by Distribution Channel
• Exhibit 06: Executive Summary – Chart on Market Segmentation by Type
• Exhibit 07: Executive Summary – Chart on Incremental Growth
• Exhibit 08: Executive Summary – Data Table on Incremental Growth
• Exhibit 09: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

• 2.1 Market ecosystem
• Exhibit 10: Parent market
• Exhibit 11: Market Characteristics

3 Market Sizing

• 3.1 Market definition
• Exhibit 12: Offerings of vendors included in the market definition

• 3.2 Market segment analysis 
• Exhibit 13: Market segments

• 3.3 Market size 2022

• 3.4 Market outlook: Forecast for 2022-2027 
• Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ billion)
• Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ billion)
• Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
• Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)

4 Five Forces Analysis

• 4.1 Five forces summary
• Exhibit 18: Five forces analysis - Comparison between 2022 and 2027

• 4.2 Bargaining power of buyers 
• Exhibit 19: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027

• 4.3 Bargaining power of suppliers 
• Exhibit 20: Bargaining power of suppliers – Impact of key factors in 2022 and 2027

• 4.4 Threat of new entrants 
• Exhibit 21: Threat of new entrants – Impact of key factors in 2022 and 2027

• 4.5 Threat of substitutes 
• Exhibit 22: Threat of substitutes – Impact of key factors in 2022 and 2027

• 4.6 Threat of rivalry
• Exhibit 23: Threat of rivalry – Impact of key factors in 2022 and 2027

• 4.7 Market condition
• Exhibit 24: Chart on Market condition - Five forces 2022 and 2027

5 Market Segmentation by Distribution Channel

• 5.1 Market segments
• Exhibit 25: Chart on Distribution Channel - Market share 2022-2027 (%)
• Exhibit 26: Data Table on Distribution Channel - Market share 2022-2027 (%)

• 5.2 Comparison by Distribution Channel 
• Exhibit 27: Chart on Comparison by Distribution Channel
• Exhibit 28: Data Table on Comparison by Distribution Channel

• 5.3 Hospital pharmacy - Market size and forecast 2022-2027 
• Exhibit 29: Chart on Hospital pharmacy - Market size and forecast 2022-2027 ($ billion)
• Exhibit 30: Data Table on Hospital pharmacy - Market size and forecast 2022-2027 ($ billion)
• Exhibit 31: Chart on Hospital pharmacy - Year-over-year growth 2022-2027 (%)
• Exhibit 32: Data Table on Hospital pharmacy - Year-over-year growth 2022-2027 (%)

• 5.4 Retail pharmacy - Market size and forecast 2022-2027 
• Exhibit 33: Chart on Retail pharmacy - Market size and forecast 2022-2027 ($ billion)
• Exhibit 34: Data Table on Retail pharmacy - Market size and forecast 2022-2027 ($ billion)
• Exhibit 35: Chart on Retail pharmacy - Year-over-year growth 2022-2027 (%)
• Exhibit 36: Data Table on Retail pharmacy - Year-over-year growth 2022-2027 (%)

• 5.5 Others - Market size and forecast 2022-2027 
• Exhibit 37: Chart on Others - Market size and forecast 2022-2027 ($ billion)
• Exhibit 38: Data Table on Others - Market size and forecast 2022-2027 ($ billion)
• Exhibit 39: Chart on Others - Year-over-year growth 2022-2027 (%)
• Exhibit 40: Data Table on Others - Year-over-year growth 2022-2027 (%)

• 5.6 Market opportunity by Distribution Channel 
• Exhibit 41: Market opportunity by Distribution Channel ($ billion)

6 Market Segmentation by Type

• 6.1 Market segments
• Exhibit 42: Chart on Type - Market share 2022-2027 (%)
• Exhibit 43: Data Table on Type - Market share 2022-2027 (%)

• 6.2 Comparison by Type
• Exhibit 44: Chart on Comparison by Type
• Exhibit 45: Data Table on Comparison by Type

• 6.3 Alcohol addiction therapeutics - Market size and forecast 2022-2027 
• Exhibit 46: Chart on Alcohol addiction therapeutics - Market size and forecast 2022-2027 ($ billion)
• Exhibit 47: Data Table on Alcohol addiction therapeutics - Market size and forecast 2022-2027 ($ billion)
• Exhibit 48: Chart on Alcohol addiction therapeutics - Year-over-year growth 2022-2027 (%)
• Exhibit 49: Data Table on Alcohol addiction therapeutics - Year-over-year growth 2022-2027 (%)

• 6.4 Tobacco addiction therapeutics - Market size and forecast 2022-2027 
• Exhibit 50: Chart on Tobacco addiction therapeutics - Market size and forecast 2022-2027 ($ billion)
• Exhibit 51: Data Table on Tobacco addiction therapeutics - Market size and forecast 2022-2027 ($ billion)
• Exhibit 52: Chart on Tobacco addiction therapeutics - Year-over-year growth 2022-2027 (%)
• Exhibit 53: Data Table on Tobacco addiction therapeutics - Year-over-year growth 2022-2027 (%)

• 6.5 Drug addiction therapeutics - Market size and forecast 2022-2027 
• Exhibit 54: Chart on Drug addiction therapeutics - Market size and forecast 2022-2027 ($ billion)
• Exhibit 55: Data Table on Drug addiction therapeutics - Market size and forecast 2022-2027 ($ billion)
• Exhibit 56: Chart on Drug addiction therapeutics - Year-over-year growth 2022-2027 (%)
• Exhibit 57: Data Table on Drug addiction therapeutics - Year-over-year growth 2022-2027 (%)

• 6.6 Market opportunity by Type 
• Exhibit 58: Market opportunity by Type ($ billion)

7 Customer Landscape

• 7.1 Customer landscape overview 
• Exhibit 59: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

8 Geographic Landscape

• 8.1 Geographic segmentation 
• Exhibit 60: Chart on Market share by geography 2022-2027 (%)
• Exhibit 61: Data Table on Market share by geography 2022-2027 (%)

• 8.2 Geographic comparison 
• Exhibit 62: Chart on Geographic comparison
• Exhibit 63: Data Table on Geographic comparison

• 8.3 North America - Market size and forecast 2022-2027 
• Exhibit 64: Chart on North America - Market size and forecast 2022-2027 ($ billion)
• Exhibit 65: Data Table on North America - Market size and forecast 2022-2027 ($ billion)
• Exhibit 66: Chart on North America - Year-over-year growth 2022-2027 (%)
• Exhibit 67: Data Table on North America - Year-over-year growth 2022-2027 (%)

• 8.4 Europe - Market size and forecast 2022-2027 
• Exhibit 68: Chart on Europe - Market size and forecast 2022-2027 ($ billion)
• Exhibit 69: Data Table on Europe - Market size and forecast 2022-2027 ($ billion)
• Exhibit 70: Chart on Europe - Year-over-year growth 2022-2027 (%)
• Exhibit 71: Data Table on Europe - Year-over-year growth 2022-2027 (%)

• 8.5 Asia - Market size and forecast 2022-2027 
• Exhibit 72: Chart on Asia - Market size and forecast 2022-2027 ($ billion)
• Exhibit 73: Data Table on Asia - Market size and forecast 2022-2027 ($ billion)
• Exhibit 74: Chart on Asia - Year-over-year growth 2022-2027 (%)
• Exhibit 75: Data Table on Asia - Year-over-year growth 2022-2027 (%)

• 8.6 Rest of World (ROW) - Market size and forecast 2022-2027 
• Exhibit 76: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ billion)
• Exhibit 77: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ billion)
• Exhibit 78: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
• Exhibit 79: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)

• 8.7 US - Market size and forecast 2022-2027 
• Exhibit 80: Chart on US - Market size and forecast 2022-2027 ($ billion)
• Exhibit 81: Data Table on US - Market size and forecast 2022-2027 ($ billion)
• Exhibit 82: Chart on US - Year-over-year growth 2022-2027 (%)
• Exhibit 83: Data Table on US - Year-over-year growth 2022-2027 (%)

• 8.8 Germany - Market size and forecast 2022-2027 
• Exhibit 84: Chart on Germany - Market size and forecast 2022-2027 ($ billion)
• Exhibit 85: Data Table on Germany - Market size and forecast 2022-2027 ($ billion)
• Exhibit 86: Chart on Germany - Year-over-year growth 2022-2027 (%)
• Exhibit 87: Data Table on Germany - Year-over-year growth 2022-2027 (%)

• 8.9 Canada - Market size and forecast 2022-2027 
• Exhibit 88: Chart on Canada - Market size and forecast 2022-2027 ($ billion)
• Exhibit 89: Data Table on Canada - Market size and forecast 2022-2027 ($ billion)
• Exhibit 90: Chart on Canada - Year-over-year growth 2022-2027 (%)
• Exhibit 91: Data Table on Canada - Year-over-year growth 2022-2027 (%)

• 8.10 UK - Market size and forecast 2022-2027 
• Exhibit 92: Chart on UK - Market size and forecast 2022-2027 ($ billion)
• Exhibit 93: Data Table on UK - Market size and forecast 2022-2027 ($ billion)
• Exhibit 94: Chart on UK - Year-over-year growth 2022-2027 (%)
• Exhibit 95: Data Table on UK - Year-over-year growth 2022-2027 (%)

• 8.11 France - Market size and forecast 2022-2027 
• Exhibit 96: Chart on France - Market size and forecast 2022-2027 ($ billion)
• Exhibit 97: Data Table on France - Market size and forecast 2022-2027 ($ billion)
• Exhibit 98: Chart on France - Year-over-year growth 2022-2027 (%)
• Exhibit 99: Data Table on France - Year-over-year growth 2022-2027 (%)

• 8.12 Market opportunity by geography 
• Exhibit 100: Market opportunity by geography ($ billion)

9 Drivers, Challenges, and Trends

• 9.1 Market drivers

• 9.2 Market challenges

• 9.3 Impact of drivers and challenges 
• Exhibit 101: Impact of drivers and challenges in 2022 and 2027

• 9.4 Market trends

10 Vendor Landscape

• 10.1 Overview

• 10.2 Vendor landscape
• Exhibit 102: Overview on Criticality of inputs and Factors of differentiation

• 10.3 Landscape disruption
• Exhibit 103: Overview on factors of disruption

• 10.4 Industry risks
• Exhibit 104: Impact of key risks on business

11 Vendor Analysis

• 11.1 Vendors covered
• Exhibit 105: Vendors covered

• 11.2 Market positioning of vendors 
• Exhibit 106: Matrix on vendor position and classification

• 11.3 Alkermes Public Ltd. Co. 
• Exhibit 107: Alkermes Public Ltd. Co. - Overview
• Exhibit 108: Alkermes Public Ltd. Co. - Product / Service
• Exhibit 109: Alkermes Public Ltd. Co. - Key news
• Exhibit 110: Alkermes Public Ltd. Co. - Key offerings

• 11.4 Amneal Pharmaceuticals Inc. 
• Exhibit 111: Amneal Pharmaceuticals Inc. - Overview
• Exhibit 112: Amneal Pharmaceuticals Inc. - Business segments
• Exhibit 113: Amneal Pharmaceuticals Inc. - Key news
• Exhibit 114: Amneal Pharmaceuticals Inc. - Key offerings
• Exhibit 115: Amneal Pharmaceuticals Inc. - Segment focus

• 11.5 Aphios Corp.
• Exhibit 116: Aphios Corp. - Overview
• Exhibit 117: Aphios Corp. - Product / Service
• Exhibit 118: Aphios Corp. - Key offerings

• 11.6 Braeburn Inc.
• Exhibit 119: Braeburn Inc. - Overview
• Exhibit 120: Braeburn Inc. - Product / Service
• Exhibit 121: Braeburn Inc. - Key offerings

• 11.7 Emergent BioSolutions Inc. 
• Exhibit 122: Emergent BioSolutions Inc. - Overview
• Exhibit 123: Emergent BioSolutions Inc. - Product / Service
• Exhibit 124: Emergent BioSolutions Inc. - Key news
• Exhibit 125: Emergent BioSolutions Inc. - Key offerings

• 11.8 GlaxoSmithKline Plc
• Exhibit 126: GlaxoSmithKline Plc - Overview
• Exhibit 127: GlaxoSmithKline Plc - Business segments
• Exhibit 128: GlaxoSmithKline Plc - Key offerings
• Exhibit 129: GlaxoSmithKline Plc - Segment focus

• 11.9 Glenmark Pharmaceuticals Ltd. 
• Exhibit 130: Glenmark Pharmaceuticals Ltd. - Overview
• Exhibit 131: Glenmark Pharmaceuticals Ltd. - Product / Service
• Exhibit 132: Glenmark Pharmaceuticals Ltd. - Key offerings

• 11.10 Hikma Pharmaceuticals Plc 
• Exhibit 133: Hikma Pharmaceuticals Plc - Overview
• Exhibit 134: Hikma Pharmaceuticals Plc - Business segments
• Exhibit 135: Hikma Pharmaceuticals Plc - Key offerings
• Exhibit 136: Hikma Pharmaceuticals Plc - Segment focus

• 11.11 Indivior Plc
• Exhibit 137: Indivior Plc - Overview
• Exhibit 138: Indivior Plc - Product / Service
• Exhibit 139: Indivior Plc - Key offerings

• 11.12 Mallinckrodt Plc
• Exhibit 140: Mallinckrodt Plc - Overview
• Exhibit 141: Mallinckrodt Plc - Business segments
• Exhibit 142: Mallinckrodt Plc - Key news
• Exhibit 143: Mallinckrodt Plc - Key offerings
• Exhibit 144: Mallinckrodt Plc - Segment focus

• 11.13 Orexo AB
• Exhibit 145: Orexo AB - Overview
• Exhibit 146: Orexo AB - Product / Service
• Exhibit 147: Orexo AB - Key offerings

• 11.14 Otsuka Holdings Co. Ltd. 
• Exhibit 148: Otsuka Holdings Co. Ltd. - Overview
• Exhibit 149: Otsuka Holdings Co. Ltd. - Business segments
• Exhibit 150: Otsuka Holdings Co. Ltd. - Key offerings
• Exhibit 151: Otsuka Holdings Co. Ltd. - Segment focus

• 11.15 Pfizer Inc.
• Exhibit 152: Pfizer Inc. - Overview
• Exhibit 153: Pfizer Inc. - Product / Service
• Exhibit 154: Pfizer Inc. - Key news
• Exhibit 155: Pfizer Inc. - Key offerings

• 11.16 Teva Pharmaceutical Industries Ltd. 
• Exhibit 156: Teva Pharmaceutical Industries Ltd. - Overview
• Exhibit 157: Teva Pharmaceutical Industries Ltd. - Business segments
• Exhibit 158: Teva Pharmaceutical Industries Ltd. - Key news
• Exhibit 159: Teva Pharmaceutical Industries Ltd. - Key offerings
• Exhibit 160: Teva Pharmaceutical Industries Ltd. - Segment focus

• 11.17 Titan Pharmaceuticals Inc. 
• Exhibit 161: Titan Pharmaceuticals Inc. - Overview
• Exhibit 162: Titan Pharmaceuticals Inc. - Product / Service
• Exhibit 163: Titan Pharmaceuticals Inc. - Key offerings

12 Appendix

• 12.1 Scope of the report

• 12.2 Inclusions and exclusions checklist 
• Exhibit 164: Inclusions checklist
• Exhibit 165: Exclusions checklist

• 12.3 Currency conversion rates for US$ 
• Exhibit 166: Currency conversion rates for US$

• 12.4 Research methodology
• Exhibit 167: Research methodology
• Exhibit 168: Validation techniques employed for market sizing
• Exhibit 169: Information sources

• 12.5 List of abbreviations 
• Exhibit 170: List of abbreviations

• health: Includes veterinary drugs (excluded from the scope of the report) 

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contact
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/

SOURCE Technavio